The adequate treatment for
Hurthle cell carcinomas is the surgical method.
Size of
Hurthle cell neoplasm is the only parameter which is predictive of malignancy.
Urbach, "The treatment and prognosis of
Hurthle cell follicular thyroid carcinoma compared with its non-Hurthle cell counterpart," Surgery, vol.
Hurthle cell carcinoma: an update on survival over the last 35 years.
In the parathyroids these are called as oxyphilic cells,
hurthle cells in thyroid and oncocytes in pituitary, salivary glands, breast and kidney.
* Malignant including PTC, follicular thyroid carcinoma (FTC), MTC,
Hurthle cell carcinoma (HCC), anaplastic carcinoma, or metastatic carcinoma.
While PET-CT has proved itself in this clinical scenario, evidence is emerging on the advantages of PET-CT imaging in other histological types of thyroid malignancy, such as
Hurthle cell, medullary, and the anaplastic variants.
Baseline characteristics of patients Characteristics Age 47 [+ or -] 13 Histology PTC 152 (92.7%) FTC 11 (6.7%) HCC 1 (0.6%) TNM Stage I 130 (79.3%) II 20 (12.2%) III 13 (7.9%) IV 1 (0.6%) Administered Activity (MBq/mCi) Mean[+ or -]SD 4144 [+ or -] 851 (112.74 [+ or -] 23) Median 3700 (100) Range 3700-7400 (100-200) Post-Therapy Scan Thyroid remnant 156 (95.1%) Lymph node metastases 7 (4.3%) Pulmonary metastases 1 (0.6%) Bone metastases 0 (0%) PTC: Papillary thyroid cancer; FTC: Follicular thyroid carcinoma; HCC: Thyroid carcinoma,
Hurthle cell; TNM: TNM staging system (tumor, node, metastasis) Table 2.
We examined 56 FFPE tissue samples from follicular neoplasms for which clinical data and sufficient tissue were available [32 FA, 19
Hurthle cell carcinomas (HCC), and 10 FTC cases].
The new guidelines recommend that PET scans also may be used as part of initial staging in poorly differentiated thyroid cancers and invasive
Hurthle cell carcinomas, as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality, and as an evaluation of posttreatment response following systemic or local therapy of metastatic or locally invasive disease.
The new guideline recommends that PET scans also may be used "as part of initial staging in poorly differentiated thyroid cancers and invasive
Hurthle cell carcinomas, especially those with other evidence of disease on imaging or because of elevated serum thyroglobulin levels; as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality; and as an evaluation of posttreatment response following systemic or local therapy of metastatic or locally invasive disease."
part owner and salesman for Specialty Chemical Sales, lost his battle against
Hurthle cell thyroid cancer, a rare type of thyroid cancer.
